These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35159005)

  • 1. Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.
    Mancini M; Monaldi C; De Santis S; Rondoni M; Papayannidis C; Sartor C; Curti A; Bruno S; Cavo M; Soverini S
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Castagnetti F; Lonetti A; Bruno S; Dan E; Sinigaglia B; Rosti G; Cavo M; Gugliotta G; Soverini S
    Front Oncol; 2022; 12():901132. PubMed ID: 35992847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
    Mancini M; Monaldi C; De Santis S; Papayannidis C; Rondoni M; Sartor C; Bruno S; Pagano L; Criscuolo M; Zanotti R; Bonifacio M; Tosi P; Arock M; Valent P; Cavo M; Soverini S
    Biomark Res; 2023 Mar; 11(1):29. PubMed ID: 36894973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
    Peter B; Gleixner KV; Cerny-Reiterer S; Herrmann H; Winter V; Hadzijusufovic E; Ferenc V; Schuch K; Mirkina I; Horny HP; Pickl WF; Müllauer L; Willmann M; Valent P
    Haematologica; 2011 May; 96(5):672-80. PubMed ID: 21242189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.
    Serpico AF; D'Alterio G; Vetrei C; Della Monica R; Nardella L; Visconti R; Grieco D
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31200459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
    Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
    Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
    Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
    Front Immunol; 2018; 9():631. PubMed ID: 29643855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
    Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability.
    Zhang M; Dominguez D; Chen S; Fan J; Qin L; Long A; Li X; Zhang Y; Shi H; Zhang B
    Oncol Lett; 2017 Sep; 14(3):3580-3586. PubMed ID: 28927115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.
    Chilamakuri R; Rouse DC; Agarwal S
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.
    Van den Bossche J; Domen A; Peeters M; Deben C; De Pauw I; Jacobs J; De Bruycker S; Specenier P; Pauwels P; Vermorken JB; Lardon F; Wouters A
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
    Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma.
    Pandey A; Tripathi SC; Mai J; Hanash SM; Shen H; Mitra S; Rostomily RC
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.